From spatial biology to clinical utility: Advancing lung cancer diagnostics

Dr. Carlo Bifulco, Chief Medical Officer at Providence Genomics and Director of Translational Molecular Pathology at EACRI

Xiaoshan Wang, VP of Business Development for Spatomics

November 8, 2025

About this webinar

The SITC 2025 session, “From spatial biology to clinical utility: Advancing lung cancer diagnostics,” explores cutting-edge advancements in spatial biology technologies and their transformative potential in improving lung cancer diagnosis and treatment strategies. The discussion features insights from Dr. Carlo Bifulco, Chief Medical Officer at Providence Genomics and Director of Translational Molecular Pathology at EACRI, and Xiaoshan Wang, VP of Business Development for Spatomics, and, who share perspectives from both industry and clinical research.

 

Highlights:

  • Emerging spatial biology tools enable high-resolution mapping of tumor microenvironments, revealing critical insights into lung cancer heterogeneity.
  • Integration of multiplex imaging and AI-driven analytics enhances the identification of predictive biomarkers for personalized therapy.
  • Translational research is bridging discoveries from the lab to clinical applications, supporting earlier and more accurate lung cancer detection.
  • Collaborative efforts between academia, industry, and diagnosticians —including contributions from Wang and Bifulco—are accelerating the validation and adoption of spatial diagnostics.

About the presenters

Dr. Carlo Bifulco brings over 18 years of experience in pathology, genomics, and molecular diagnostics to his role as Chief Medical Officer of Providence Genomics, a division of Providence that leverages artificial intelligence and advanced technologies to transform healthcare delivery and outcomes. In this role, he oversees the development and implementation of genomic and molecular testing services, clinical trials, and research collaborations across the Providence network. Dr. Bifulco also serves as the Medical Director of Translational Pathology at the Earle A. Chiles Research Institute, where he leads a team of pathologists and scientists in applying cutting-edge fluorescence microscopy and image analysis techniques to study the tumor microenvironment and immune response. His core competencies include developing and executing strategic vision, fostering innovation and collaboration, and translating scientific discoveries into clinical applications. Dr. Bifulco is passionate about advancing the field of precision medicine and improving the lives of patients with cancer and other diseases.

 

Xiaoshan Wang has more than 10 years experiences in sample preparation, next generation sequencing (NGS), genomics, digital pathology, and clinical applications. Rich experience in product management. Xiaoshan received his molecular biology training at Virginia Tech and obtained his MBA from University of California, Berkeley, Haas School of Business. As a result driven business professional, he focuses on product management and strategic marketing in life science and in vitro diagnostics (IVD) industries.